- About Us
- Guidelines
-
The Author ensures that the research has been conducted responsibly and ethically with adherence to all relevant regulations. read more..
- For Authors
- For Reviewer
- Manuscript Guidelines
- Membership
-
- Journals
- Reprints
- e-Books
- Videos
- Indexing
- Contact Us
COVID-19
- Submissions
Abstract
Gastroenterology Medicine & Research
Insulin Therapy and Cardiovascular Outcome Trials (Cvots): Any Harm, Anytime?
-
Open or Close Uche Anyanwagu1* and Ifeoma Ezegbulam2
1University of Nottingham, Royal Derby Hospital, UK
2Adonai Hospitals, Nigeria
*Corresponding author: Uche Anyanwagu, Division of Graduate Entry Medicine, School of Medicine, Derby, University of Nottingham, Royal Derby Hospital, UK
Submission: February 25, 2018; Published: March 21, 2018
ISSN 2637-7632Volume1 Issue3
Abstract
The therapeutic management of diabetes may on its own increase the risk of cardiovascular (CV) risk markers – directly or indirectly – through their pharmacological actions (e.g. side effects as hypoglycaemia), or some metabolic changes (e.g. weight-gain, increased BP, etc.). As these risks may not have been anticipated or immediately noticed during clinical trials, 1 post hoc analyses and epidemiological follow up of clinical trials have raised concerns about the CV safety of some drugs used in the management of diabetes.
Editor In Chief
.jpg)
Signup for Newsletter
Quick Links
Editorial Board Registrations
Submit your Article
Best Paper of the Volume
Reprints
Refer a Friend
Advertise With UsOur Recent Edition
.jpg)
Top Editors
.jpg)
.bmp)
.jpg)
.png)
.jpg)
.png)
.png)
.png)
Financial Support
Sponsors
Latest e-Books
Latest Video
a Creative Commons Attribution 4.0 International License. Based on a work at www.crimsonpublishers.com.
Best viewed in 
| Above IE 9.0 version